Neonatal Derived Mesenchymal Stem Cell Mesotherapy in Androgenetic Alopecia: A Retrospective Observational Study and Review of Literature

The study evaluated the safety and efficacy of neonatal mesenchymal stem cell (MSC) mesotherapy in treating androgenetic alopecia (AGA) in 40 patients with AGA grades 2 to 7. After four monthly sessions, 70% of patients showed mild improvement, 25% showed moderate improvement, and one patient showed a 72% improvement in hair growth and reduction in hair loss. No major adverse events were reported. The study concluded that while the results were promising, larger randomized controlled studies with longer follow-ups were needed to establish MSC therapy as a novel treatment option for AGA.